NCT07621237招募中2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 360
- 试验地点
- 25
研究概览
简要总结
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are:
Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL?
Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder.
Participants will:
Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary DSM-5 diagnosis of current MDD.
- •The duration of the current MDE must be between 6 weeks and 18 months.
- •Without psychotic or catatonic features.
- •Capable of reading and understanding English and able to provide written informed consent to participate.
排除标准
- •Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa,
- •Diagnosis of borderline personality disorder that is known, suspected
- •Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD.
- •Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence.
- •History of substance use disorder and/or alcohol use disorder during the preceding 12 months
- •Use of antidepressants (including ketamine/esketamine, St. John's Wort, S-adenosyl methionine, and/or trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)
研究者
研究点 (25)
Loading locations...
相似试验
招募中
2 期
A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusNCT07340320Corxel Pharmaceuticals240
招募中
2 期
Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled AsthmaAsthmaNCT07589439Shanghai Novamab Biopharmaceuticals Co., Ltd.216
尚未招募
2 期
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisGeneralized Myasthenia GravisNCT07622342Guangdong Hengrui Pharmaceutical Co., Ltd60
尚未招募
3 期
Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use DisorderNCT07433413Shenzhen Sciencare Medical Industries Co., Ltd.240
尚未招募
1 期
Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)AspartylglucosaminuriaAspartylglucosamidase (AGA) DeficiencyNCT07530796Rare Trait Hope9